

Report Type: Q2FY23 Result Sector: Chemicals Date – 07<sup>th</sup> Dec 2022

# **KEY HIGHLIGHTS**

- In Q2F23, the consolidated revenue grew up by 99% at Rs 1,567 crores versus Rs 788 crores.
- Explosives revenue was up by 90%. Realization of explosives has increased by almost 73%, that is Rs 70,900 versus Rs 40,874 during 03FY23.
- Initiating Systems revenue increased by 50%. However Coal India's contribution of revenue stood at 13% compared to 15% whereas revenues increased by 67% year-on-year to Rs 198 crores from Rs 118 crores.
- PBT has increased by massive 144% from Rs 104 crores to Rs 254 crores & PAT has increased by 152% from Rs 75 crores to INR Rs crores in Q3FY23.

#### 1. MANAGEMENT COMMENTARY:

- Management have given a guidance of 15% volume growth for the whole financial year as more volumes are expected in the second half since the first half always have lower demand due to monsoon. The export volumes are also expected to be around 15% to 16% year-onyear basis.
- The management has revised revenue guidance of around 50% instead of 30% on the basis of better realization in input prices and the improved sales from its overseas subsidiaries and management stated that defense business has also given an upward trajectory.
- Going forward, for the whole year, company maintain the EBIDTA guidance of 18% to 20% & 11% to 12% for PAT.
- Management indicated that the share of Coal India, which was around, 14%-15% on the half yearly basis will be likely to remain around 10% to 15% & will not cross more than that.
- Company's overseas expansions are materializing in the last few years.
   South Africa, Australia has started given the better results as compare to last financial year. Since, company is having growth from across the all geographies hence based on that company is likely to have around 15% volume growth, from India as well as outside.
- For the current year, company have a capex plan of around Rs 300 crores to Rs 500 crores.
- As a part of its policy, company have been maintaining the debt equity around 0.5 or lower than 0.5.

## 2. OTHER DEVELOPMENTS:

- As company's product portfolio covers variety of offerings for different applications like high energy materials, pyros, propylenes, rockets and war heads, company have now entered into the drone with ammunition also.
- Company has received export order of INR 300 crores in the RFP for Pinaka & the likely time line is next two years. So company expects to commence the production from the Q1 of the next financial year and likely to finish in 12 months to 18 months' time.

#### 4. VALUATION AND OUTLOOK:

- The company is currently trading at 48x of FY23E eps & 39x of FY24E eps.
- Company has shown strong financial performance along with robust orderbook of Rs 4008 Cr.
- Company's strategy to grow overseas businesses, expanding non-coal India markets and defense continues to boost its performances. Exports and overseas business has outperformed by showing a growth of 107% year-on-year. Defense business has achieved another milestone by crossing INR 100 crores in this quarter. Therefore, company after establishing in Indian ammunition market, is looking forward for export opportunities that are providing a new avenue of growth and company is first private sector company in India to receive order for exports. This in turn lead the management to revise its annual revenue growth for FY23 from 30% to around 50%
- Hence, we recommend BUY on stock with price target of Rs 4620 ( up 15%) in medium term.

# RECOMMENDATION – BUY CMP –4007.45 TARGET - 4620

Industry	Chemicals
NSE CODE	SOLARINDS
BSE CODE	532725
Market Cap (₹ Cr)	36263.44
Shares Outstanding (in	9.05
Cr)	
52 wk High/Low (₹)	4269.40/2160.05
P/E	58.81
P/BV	16.58
Face Value (₹)	2.00
Book Value(TTM) (₹)	241.67
EPS (TTM)(₹)	68.14
Dividend Yield (%)	0.18
Debt / Equity	0.45

## **SHAREHOLDING PATTERN**

	Sept'22	Jun' 22	Sept' 21
Promoters	73.15	73.2	15 73.15
Mutual Funds	14.25	5 14.4	45 15.61
FII/FPI	6.64	1 6.6	5.81
Alternate Investment Fund	0.33	3 0.2	27 0.01
Retail & Others	5.63	5.50	5.43
Promoter Pledging	0.00	0.00	0.00

#### FINANCIAL SNAPSHOT (₹ CR)

Y/E			
March	2022A	2023E	2024E
Sales	3947.61	6216.55	8081.51
Sales Gr. (%)		57.47	29.99
EBITDA	734.56	1243.31	1535.00
EBITDA mrg. (%)	19.25	19.99	18.99
Adj. PAT	441.28	745.98	929.37
Adj. EPS (₹)	48.76	82.43	102.69
EPS Gr. (%)		69.05	24.58
BV/Sh. (₹)	211.52	286.45	379.14
Ratios			
Valuation			
P/E (x)	82.18	48.61	39.02
P/BV (x)	18.94	13.99	10.56
Price/Sales (x)	9.19	5.83	4.48

Valuation	
Historical P/E (3 Yr	60.10
Avg)	
Industry P/E	29.75
Historical P/B (3 Yr	11.77
Avg)	
Industry P/B	5.07

Report Type: Q2FY23 Result Sector: Chemicals Date – 07<sup>th</sup> Dec 2022


# SEGMENT PERFORMANCE

# **Q2FY23 v/s Q2FY22**

#### Q21123 V/3 Q21122



**Explosives** 



**Initiating Systems Value (Cr)** 

# **QUARTERLY FINANCIALS**

(₹ Cr)

	Q3FY	Q4	Q1	Q2	Q3	Q4	Q1	Q2	FY21	FY22
	21	FY21	FY22	FY22	FY22	FY22	FY23	<b>FY23</b>	F 1 2 1	F 1 22
Net sales	645.85	791.39	825.3	787.66	1017.87	1316.85	1615.64	1566.60	2515.63	3947.61
change (%)		22.53	4.28	-4.56	29.23	29.37	22.69	-3.04		56.92
EBITDA	132.24	164.55	174.72	131.75	177.97	262.82	282.97	298.98	514.60	747.26
Margins (%)	20.48	20.79	21.17	16.73	17.48	19.96	17.51	19.08	20.45	18.93
YoY growth (%)		24.43	6.18	-24.59	35.08	47.68	7.67	5.66		45.21
Depreciation	24.36	22.53	25.18	27.25	27.19	29.63	30.54	30.35	93.53	109.25
Interest	10.94	10.48	10.26	11.80	13.41	14.78	14.27	19.41	45.39	50.25
Other income	13.23	2.44	0.80	11.02	7.07	0.77	8.58	4.36	21.42	19.66
PBT	110.17	133.98	140.08	103.72	144.44	29.18	246.74	253.58	397.10	607.42
Tax	28.74	38.94	39.23	28.95	39.38	44.39	64.09	64.89	109.03	151.95
Rate (%)	26.09	29.06	28.01	27.91	27.26	152.12	25.97	25.59	27.46	25.02
Adjusted PAT	78.04	91.02	97.51	73.79	102.09	167.89	170.21	176.38	276.35	441.28
change (%)		16.63	7.13	-24.33	38.35	64.45	1.38	3.62		59.68

Source: Company, Ace Equity Database

Report Type: Q2FY23 Result Sector: Chemicals Date – 07<sup>th</sup> Dec 2022

## **INDUSTRY OVERVIEW**

#### Industrial explosives market

In industrial explosives market CAGR is expected to grow at 5.4% between 2021 and 2027. The market is expected to reach US\$16 billion by 2027. Huge investments for mining, coupled with favourable government initiatives are expected to drive the growth of the industrial explosive industry. Demand in the Asia Pacific region is also expected to surge due to the development of housing and infrastructure projects and improvements in the public transit systems including railways and roadways. It is also expected to increase the number of road development projects and tunnelling activities, which are heavily reliant on the usage of industrial explosives. In addition, the presence of mining corporations in Australia and China are expected to improve the demand for explosives.

Indian industrial explosives industry

#### Growth drivers

**Coal mining industry**: Rapid urbanisation and development of smart cities in India is pushing the demand for new and modern infrastructure. The government is also pushing to cut down coal imports and improve domestic coal production. These factors are expected to drive the industrial explosives growth in the domestic market in the near short term.

**Global defence industry:** The defence industry has weathered the pandemic due to strong order books, and 2022 is expected to be the year where defence companies will focus on rebuilding and increase agility in operations. The global defence market is predicted to increase at a CAGR of 6.8%, from \$452.69 billion in 2021 to \$483.47 billion in 2022, as military projects continue to be a strategic priority and countries further strengthen their militaries. The industry's potential value is expected to increase due private sector innovation in digital initiatives across production and the supply network. Furthermore, new technologies, evolving business models, and increasing innovation will further accelerate the shift toward digital and operational efficiencies. The defence industry is estimated to reach \$604.82 billion by 2026, growing at a 5.8% CAGR28.


**Indian defence industry**: In the Union Budget, 2022 domestic procurement budget was increased by 10 per cent y-o-y, to 68 per cent of the budgeted Capital expenditure. Also, the government has allowed up to 74% FDI in Defence Sector through the Automatic Route for companies seeking new defence industrial licenses. These measures are expected to reduce the dependency of defence equipment through imports and drive domestic defence procurement.


#### PEER PERFORMANCE


Particulars (FY22) (Rs Cr)	Atul	Chemplast	GHCL	Solar Inds
Net Sales	5080.89	5891.99	3778.36	3947.61
PAT	596.58	648.65	598.30	441.28
PAT Margin %	11.59	11.01	15.83	11.43
ROE%	14.45	0.00	21.55	26.07
P/E	43.23	12.61	5.09	59.88
P/B	5.74	45.86	1.53	16.88
EV/EBIDTA	26.19	6.13	3.85	36.37
Mcap/Sales	4.59	1.18	1.68	6.69


Source: Ace Equity Database


Report Type: Q2FY23 Result Sector: Chemicals Date – 07<sup>th</sup> Dec 2022
















Report Type: Q2FY23 Result Sector: Chemicals Date – 07<sup>th</sup> Dec 2022

# **INVESTMENT RATIONALE:**

**Healthy Sectoral demand** – The overall energy consumption of India continues to rise and with the nascent supply of renewable energy, the demand for coal is expected to increase in future. Also, favourable government schemes due to government's emphasis on 'Make in India' to create 'Atmanirbhar Bharat' has reduced dependence on import and increased domestic demand for defence manufacturing in India. In 2021, a new scheme under Make in India was launched to promote MSMEs in the defence exports market. The defence procurement policy 2020 underwent significant reforms and increased the automatic approval of FDI from 49% to 74%. It is expected to attract foreign funding to India's defence sector. All this will help the company in gaining strong demand going ahead.

➤ Strong Financials with robust order book – Company has posted strong financials along with the strong order book of INR 4,000 crores-plus, which includes defense orders of INR 885 crores. This gives strong revenue visibility going ahead as management has revised its guidance of annual revenue growth for FY23 from 30% to around 50% on back of higher realization in input prices and the improved sales from company's overseas subsidiaries along with the healthy Defense business.

# **RISK FACTORS:**

- Increase in Input cost
- Increase in Competitive intensity

# **COMPANY RECAP:**

- Solar Industries India Limited(Solar) is a global manufacturer of industrial explosives and initiating systems. Leveraging its early-mover advantage as a private player in the defence sector, it now stands at an inflection point to capitalise on emerging opportunities in the sector.
- Solar have also successfully commenced commercial execution of Multi Mode Hand Grenades (MMHG) orders from the defence industry. The defence sector continues to contribute to company's top line along with other industries like mining, exports, overseas markets, housing and infrastructure.
- Solar will be the first Indian company to fully indigenise and develop loitering munitions (LM) in-house.
- **Industrial Explosives**: Industrial explosives comprise:
  - o Bulk Explosives
  - Packaged Explosives
  - Initiating Systems
- Defence Products:
- High Energy Materials (HMX, RDX, TNT & Compounds)
- o Composite Propellants for (Pinaka, Akash, Brahmos etc.)
- Explosives Filling of Ammunitions
- o Mines, Multi-Mode Hand Grenade, Warheads
- o Fuses, Pyros and Ignitiors
- Rocket Integration

Report Type: Q2FY23 Result Sector: Chemicals Date – 07<sup>th</sup> Dec 2022

ANNUAL PERFO	RMANCE					
Income Statement						
(Rs Cr)	FY22	FY21	FY20	FY19	FY18	FY17
Net Sales	3947.61	2515.63	2237.30	2461.57	1916.12	1579.99
Growth %	56.92	12.44	-9.11	28.47	21.27	
Total Expenditure	3213.05	2001.03	1802.98	1959.63	1515.30	1256.10
EBIDTA	734.56	514.60	434.32	501.94	400.82	323.89
Growth %	42.74	18.48	-13.47	25.23	23.75	
Other Income	32.36	21.42	41.05	14.72	22.83	13.21
EBIDT	766.92	536.02	475.37	516.66	423.65	337.10
Interest	50.25	45.39	55.04	49.87	32.72	26.89
PBDT	716.67	490.63	420.33	466.79	390.93	310.21
Depreciation	109.25	93.53	84.53	58.89	51.29	38.74
PBT	607.42	397.10	335.80	407.90	339.64	271.47
Exceptional item				-6.05		
PBT	607.42	397.10	335.80	401.85	339.64	271.47
Tax	151.95	109.03	57.13	125.05	106.05	76.74
PAT	455.47	288.07	278.67	276.80	233.59	194.73
Minority Interest	-14.19	-11.72	-11.24	-15.19	-13.04	-8.19
Consolidated Net						
Profit	441.28	276.35	267.43	261.61	220.55	186.54
Growth %	59.68	3.34	2.22	18.62	18.23	

# **Balance Sheet**

(Rs Cr)	FY22	FY21	FY20	FY19	FY18	FY17
LIABILITIES						
Share Capital	18.10	18.10	18.10	18.10	18.10	18.10
Share Warrants & Outstandings	0.00	0.00	0.00	0.00	0.00	0.00
Total Reserves	1896.18	1561.31	1361.99	1220.23	1065.76	910.49
Shareholder's Funds	1914.28	1579.41	1380.09	1238.33	1083.86	928.59
Minority Interest	100.63	62.69	51.51	47.55	47.38	40.26
Secured Loans	397.89	401.41	252.80	151.56	196.10	147.96
Unsecured Loans	37.97	31.80				
Deferred Tax Asset	42.26	46.13	53.33	90.36	93.93	78.44
Other Long Term Liabilities	17.51	16.60	8.68		0.54	
Long term Trade payables		1.04	0.31	0.53		
Long Term Provisions	1.00	0.91	1.92	0.15	0.18	
Total Current Liabilities	1117.88	819.43	732.15	724.47	565.98	526.50
Total Liabilities	3629.42	2959.42	2480.79	2252.95	1987.97	1721.75
ASSETS						
Gross Block	1928.76	1622.57	1455.90	1213.56	1037.78	839.76
Less: Acc Depreciation	436.03	335.04	247.35	170.68	114.50	62.99
Net Block	1492.73	1287.53	1208.55	1042.88	923.28	776.77
Capital WIP	221.13	282.37	152.23	165.56	96.84	90.93
Intangible asset	9.24	10.51	12.74	12.00	10.56	
Non Current Investments	18.22	0.97	2.33	2.56	3.04	3.50
Long term loans & Advances	95.88	67.83	98.24	54.30	106.67	94.22
Other Non Current Assets	128.36	84.55	23.20	13.15	28.90	24.40
Total Non Current Assets	1965.56	1733.76	1497.29	1290.45	1169.29	989.82
Current Investments			0.02	30.08	14.01	49.75
Inventories	718.87	440.49	330.98	282.74	232.42	181.07
Sundry Debtors	541.10	455.48	370.32	399.04	363.58	319.06
Cash and Bank	98.75	181.20	120.14	91.76	69.46	39.39
Other Current Assets	102.86	85.45	96.09	103.61	65.54	64.01
Short Term Loans & Advances	202.28	63.04	65.95	55.27	73.67	78.65
Total Current Assets	1663.86	1225.66	983.50	962.50	818.68	731.93
Total Assets	3629.42	2959.42	2480.79	2252.95	1987.97	1721.75



# BROKING | INVESTMENT BANKING | RESEARCH | DISTRIBUTION | DEPOSITORY | PMS

# SOLAR INDUSTRIES INDIA LTD

Report Type: Q2FY23 Result Sector: Chemicals Date – 07<sup>th</sup> Dec 2022

Ratios						
Rs Cr	FY22	FY21	FY20	FY19	FY18	FY17
Earnings Per Share						
(Rs)	48.76	30.54	29.55	28.91	24.37	20.61
CEPS(Rs)	62.40	42.17	40.13	37.09	31.48	25.80
DPS(Rs)	7.50	6.00	6.00	7.00	6.00	5.00
Book Value (Rs)	211.52	174.52	152.50	136.83	119.76	102.61
Dividend Pay Out						
Ratio(%)	15.38	19.65	20.30	24.22	24.62	24.26
Margin Ratios						
PBIDTM (%)	19.25	21.02	21.25	20.99	21.71	19.70
PATM (%)	11.43	11.30	12.46	11.24	11.97	11.38
Performance Ratios						
ROA (%)	13.83	10.59	11.77	13.05	12.59	12.04
ROE (%)	26.07	19.47	21.29	23.84	23.21	22.46
ROCE (%)	25.56	19.87	19.89	26.24	24.57	22.67
Asset Turnover(x)	1.21	0.94	0.95	1.16	1.05	1.06
Inventory Turnover(x)	6.87	6.61	7.29	9.56	9.44	10.04
Debtors Turnover(x)	8.00	6.18	5.82	6.46	5.72	5.80
Fixed Asset Turnover						
(x)	2.24	1.66	1.68	2.19	2.08	2.01
Sales/Working Capital						
(x)	7.30	6.28	8.90	10.34	7.72	8.33
Efficiency Ratios						
Fixed Capital/Sales(x)	0.45	0.60	0.60	0.46	0.48	0.50
Receivable days	45.64	59.10	62.76	56.54	63.84	62.93
Inventory days	53.10	55.21	50.06	38.19	38.67	36.36
Payable days	38.93	51.02	31.41	29.72	28.88	29.94
Financial Stability						
Ratios						
Total Debt/Equity(x)	0.45	0.50	0.51	0.49	0.48	0.54
Current Ratio(x)	1.49	1.50	1.34	1.33	1.45	1.39

# Cash Flow Statement

Rs Cr	FY22	FY21	FY20	FY19	FY18	FY17
Profit Before Tax	607.42	397.10	335.80	401.85	339.64	271.47
Adjustment	162.27	168.94	130.31	142.72	104.26	16.94
Changes In	102.27	100.71	150.51	112.72	101.20	10.71
working Capital	-312.29	-105.27	-33.35	-101.40	-100.35	-111.76
Cash Flow after	<u> </u>					
changes in						
Working Capital	457.40	460.77	432.76	443.17	343.55	176.65
Interest Paid						
Tax Paid	-159.60	-104.09	-107.95	-129.42	-89.45	-59.03
Other Direct						
Expenses paid						
Extra & Other						
Item						
Cash From						
Operating						
Activities	297.80	356.68	324.81	313.75	254.10	117.62
Cash Flow from						
Investing						
Activities	-303.05	-250.74	-212.24	-202.26	-174.33	-170.40
Cash from						
Financing	45.40	26.05	22.62	54.54	E2 24	E2 25
Activities	-45.40	-26.07	-33.62	-51.74	-53.21	53.27
Net Cash Inflow / Outflow	F0.6F	79.87	78.95	F0.7F	26.56	0.40
	-50.65	/9.8/	/8.95	59.75	26.56	0.49
Opening Cash & Cash Equivalents	169.93	92.56	61.00	52.49	25.93	25.44
Effect of Foreign	105.53	92.30	01.00	32.47	23.73	23.44
Exchange						
Fluctuations	-34.61	-2.50	-47.39	-51.24		
Closing Cash &	51.01	2.30	17.57	J1.21		
Cash Equivalent	84.67	169.93	92.56	61.00	52.49	25.93
cash Equivalent	04.07	109.93	94.30	01.00	34.49	45.93

Source: Ace Equity Database





Report Type: Q2FY23 Result Sector: Chemicals Date – 07<sup>th</sup> Dec 2022

# RATING CRITERIA

EXPECTED RETURN
>=15%
5% to 15%
0 to 5%
-5% to 0
<-5%



Report Type: Q2FY23 Result Sector: Chemicals Date – 07<sup>th</sup> Dec 2022

I, Astha Jain, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Research Analyst or his/her relative or Hem Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or Hem Securities Ltd or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or Hem Securities Ltd. or its associate does not have any material conflict of interest.

Any holding in stock - No

Hem Securities Ltd. (HSL) is a SEBI Registered Research Analyst having registration no. INH100002250.

Disclaimer: This report has been prepared by Hem Securities Ltd. and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time. This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner. Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security. This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments. HSL and its affiliated company (IES), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company (IES) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company (IES) discussed herein or act as an advisor or lender/borrower to such company (IES) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business. HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

SEBI REGISTRATION NO.:
INZ000168034 (BSE)
INM000010981 (MERCHANT BANKER)
INH100002250 (RESEARCH ANALYST)
IN-DP-CDSL-83-2000 (DEPOSITORY PARTICIPANT)
INP000006794 (PORTFOLIO MANAGER)

HEM SECURITIES LTD.

Corporate Office: 904, Naman Midtown, Senapati Bapat Marg, Near Prabhadevi Station, Lower Parel, Mumbai- 400013. Ph- 022-49060000 Registered Office: 204, Jaipur Towers, M I Road, Jaipur- 302001. Ph- 0141-4051000 research@hemsecurities.com www.hemsecurities.com